The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) reported substantial reductions in body weight, with some participants achieving losses exceeding 20% of their baseline body weight at the highest doses studied
For forward-thinking brands, it's an invitation to innovate and create products that support metabolic and digestive health and meet consumers wherever they are on their wellness journey
Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats
Benefits include: Average weight loss of up to 15 to 25% in clinical studies Improved portion control and satiety Support for balancing blood sugar and metabolic health GLP-1/GIP Dual Agonists These advanced options activate both GLP-1 and GIP (gastric inhibitory polypeptide) receptors for enhanced appetite control, glucose balance, and fat metabolism
Receive medication from your pharmacy of choice Your prescription will be sent to your pharmacy of choice, where they will determine if prior authorization is needed